HCV Reactivation Doesn't Worsen Survival in HIV+ Lymphoma Patients

Share this content:

the Cancer Therapy Advisor take:

Results from a new study presented at ASCO 2014 indicate that reactivation of the hepatitis C virus (HCV) in HIV-positive patients with lymphoma does not worsen survival outcomes. For the study, researchers analyzed medical records of 190 HIV-positive patients diagnosed with lymphoma, 28% of whom were also infected with HCV. Reactivation of the virus occurred in about one-third of the patients with HCV, the researchers reported. Overall survival in those co-infected with HCV was 59.7 months versus 88.6 months for patients without HCV or hepatitis B virus. This difference, however, disappeared after adjustment for covariates. No significant association between overall survival and HCV virus in patients with lymphoma was found, according to the data. The researchers hope that this information will help clinical trials expand to include patients with HIV and HCV so that this unique patient population can be better understood. 

HCV Reactivation Doesn't Worsen Survival in HIV+ Lymphoma Patients
HCV Reactivation Doesn't Worsen Survival in HIV+ Lymphoma Patients
More than a quarter of HIV+ patients are also infected with the Hepatitis C virus (HCV), which may complicate treatment and care decisions after a cancer diagnosis. Barta, MD, MS, MRCP - who led the study - analyzed data from HIV+ patients diagnosed with lymphoma, collected over 17 years, to better understand how HCV infection influences survival outcomes.
READ FULL ARTICLE From Medical News Today

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs